Purpose: This study was undertaken to select the optimal combination schedule of erlotinib
and pemetrexed for the treatment of relapsed non–small cell lung cancer (NSCLC) using a …

Because the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and
the multitargeted antifolate pemetrexed are registered in the treatment of second-line non …

Purpose: Epidermal growth factor receptor (EGFR) kinase inhibitors induce dramatic clinical
responses in a subset of non-small cell lung cancer (NSCLC) patients with advanced …

Purpose A prior study demonstrated that addition of continuous daily erlotinib fails to
improve response rate or survival in non–small-cell lung cancer (NSCLC) patients treated …

BACKGROUND In this superiority study, pemetrexed was compared with erlotinib in pre‐
treated patients with metastatic non–small cell lung cancer (NSCLC). METHODS Patients …

Purpose: To examine potential markers of clinical benefit and the effects of erlotinib on the
epidermal growth factor receptor (EGFR) signaling pathway in advanced non–small cell …

BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …

Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient
population with solid tumors, identify covariates, and explore relationships between …

7519 Background: To compare the efficacy of MTA and ERL as second-line treatment of
patients with advanced/metastatic NSCLC. Methods: Pts were randomized either to MTA …

Background This randomised controlled phase 2 study compared pemetrexed and erlotinib
in combination with either agent alone in terms of efficacy and safety as second-line …